ArticleCancer chemotherapy and pharmacology2019

A phase I study of gemcitabine + dasatinib (gd) or gemcitabine + dasatinib + cetuximab (GDC) in refractory solid tumors.

Niharika B Mettu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.